Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 901–1,000 of 1,000
Choi, M. K., Cha, Y., & Baek, J. Y. (2021) · Oncology · doi:10.1159/000518041 · Cited by 3
Alghamdi, M., Bazarbashi, S. N., Mahrous, M., Alshaer, O., Gad, A., Aseafan, M., Abdelgelil, M., Alshabi, R., Alghanmi, H. A., Naser, N. A., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3796783 · Cited by 4
Liu, X., Ma, X., Ou, K., Wang, Q., Gao, L., & Yang, L. (2023) · Cancer Management and Research · doi:10.2147/cmar.s398539 · Cited by 5
Deng, T., Duan, J., Bai, M., Zhang, L., Li, H., Liu, R., Ning, T., Ge, S., Wang, X., Yang, Y., et al. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231197311 · Cited by 4
Bæksgaard, L., Yilmaz, M., Nordsmark, M., Möller, S., Elle, I. C., Ladekarl, M. B., Qvortrup, C., & Pfeiffer, P. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102521 · Cited by 4
Metastatic colorectal cancer- third line therapy and beyond
Foo, T., Roy, A. C., Karapetis, C. S., Townsend, A. R., & Price, T. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2334784 · Cited by 3
Zhong, J., Liu, Y., Qian, F., Huang, D., Gong, W., & Zou, J. (2024) · Cancer Management and Research · doi:10.2147/cmar.s464831 · Cited by 4
Silva, L. F. L., Saldanha, E. F., da Conceição, L. D., Martins, W. D. A., Gismondi, R. A., Filho, E. M. D. S., & Peixoto, R. D. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1728 · Cited by 4
André, T., Cutsem, E. V., Taïeb, J., Fakih, M., Prager, G. W., Ciardiello, F., Falcone, A., Saunders, M. P., Amellal, N., Roby, L., et al. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01261-w · Cited by 3
Self-citationIntraarterial Chemotherapy for Liver Metastases
Connell, L. C., & Kemeny, N. E. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.08.005 · Cited by 3
Omori, Y., Matsukuma, S., Kawa, M., Ishimitsu, K., Kawaoka, T., Akiyama, N., Tokuno, K., Fujita, Y., Sato, S., & Yamamoto, S. (2025) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04798-2 · Cited by 3
Pinto, C., Lonardi, S., Maiello, E., Martinelli, E., Prisciandaro, M., Salvatore, L., Bianchi, A. S., Scartozzi, M., Aprile, G., Cremolini, C., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1502185 · Cited by 4
Self-citationBellio, H., Roussot, N., Bertaut, A., Hervieu, A., Zanetta, S., Tharin, Z., Vincent, J., Bengrine-Lefèvre, L., Hennequin, A., Guion, J.-F., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2461446 · Cited by 3
Zhao, M., Jiang, Y., Shao, T., & Tang, W. (2025) · Health Economics Review · doi:10.1186/s13561-025-00622-x · Cited by 3
Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications
Emmerich, P. B., Clipson, L. J., & Deming, D. A. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0374-5 · Cited by 3
Liu, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.9574 · Cited by 3
Macaulay, R., Ahuja, A., Ademisoye, E., Juarez-Garcia, A., & Shaw, J. W. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s177343 · Cited by 3
Personalisierte Systemtherapie beim metastasierten kolorektalen Karzinom
Hofheinz, R., & Stintzing, S. (2020) · Der Internist · doi:10.1007/s00108-020-00808-x · Cited by 3
Naz, S., Farooq, U., Ma, H., Sarwar, R., & Riaz, N. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1808071 · Cited by 3
Shibutani, M., Maeda, K., Kashiwagi, S., Nagahara, H., Fukuoka, T., Iseki, Y., WANG, E., Okazaki, Y., Hirakawa, K., & Ohira, M. (2021) · Anticancer Research · doi:10.21873/anticanres.15141 · Cited by 3
Haque, E., Muhsen, I. N., Esmail, A., Umoru, G., Mylavarapu, C., Ajewole, V. B., & Abdelrahim, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.992455 · Cited by 5
Wang, M., Su, J., Lu, J., Yang, Z. X., Wang, J., Zhong, Y., Zeng, T., Shen, K., & Lin, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102078 · Cited by 3
Sugiura, K., Hiratsuka, H., Oshima, G., & Aiko, S. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad050 · Cited by 3
Radioembolisation of liver metastases
Boshell, D., & Bester, L. (2023) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13549 · Cited by 4
Prejac, J., Omrčen, T., Radić, J., Vrdoljak, E., Fröbe, A., & Pleština, S. (2023) · Oncology · doi:10.1159/000533567 · Cited by 3
Li, R., Zhou, H., Zeng, D., Jiang, S., Liu, W., Frühling, P., & Liu, Z.-Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-98 · Cited by 4
Botsen, D., Chabaud, S., Perrier, H., Ammarguellat, H., Jestin-Le-Tallec, V., Olesinski, J., Toullec, C., Aparicio, T., Abdelghani, M. B., Borg, C., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.032 · Cited by 3
Thiele, B., Stein, A., Schultheiß, C., Paschold, L., Jonas, H., Goekkurt, E., Rüssel, J., Schuch, G., Wierecky, J., Sinn, M., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.06.003 · Cited by 3
Wakasa, T., Nonaka, K., Harada, A., Ohkawa, Y., Kikutake, C., Suyama, M., Kobunai, T., Tsunekuni, K., Matsuoka, K., Kataoka, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02083-3 · Cited by 4
Malik, M., Radecka, B. S., Gełej, M., Jackowska, A., Filipczyk−Cisarż, E., Żurowska, M., Hetman, K., Foszczyńska‐Kłoda, M., Kania-Zembaczyńska, B., Mańka, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092076 · Cited by 4
Li, D., Jin, H. Z., Liu, Y., Liu, J., Zhang, X., Wang, L., Fan, Z., Li, F., Zuo, J., Han, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462346 · Cited by 4
Piercey, O., Chantrill, L. A., Hsu, H., Ma, B. B. Y., Price, T. J., Tan, I. B., Teng, H., Tie, J., & Desai, J. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14132 · Cited by 4
Aktuelle Standards in der Diagnostik und Therapie des Kolonkarzinoms
Lordick, F., & Mössner, J. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-123913 · Cited by 3
Shibutani, M., Maeda, K., Nagahara, H., Fukuoka, T., Iseki, Y., Matsutani, S., Wang, E., Hirakawa, K., & Ohira, M. (2018) · Case Reports in Oncology · doi:10.1159/000493849 · Cited by 3
Cao, M., Zhou, M., & Zhang, J. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1728860 · Cited by 6
Kimura, M., Usami, E., Teramachi, H., & Yoshimura, T. (2020) · Anticancer Research · doi:10.21873/anticanres.14108 · Cited by 3
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Vera, R., Salgado, M., Safont, M. J., Gallego-Plazas, J., González‐Flores, E., Élez, E., & Aranda, E. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02475-8 · Cited by 4
Schindler, P., Masthoff, M., Harders, F., Schmidt, H., Stegger, L., Pascher, A., Rahbar, K., Wildgruber, M., & Köhler, M. (2020) · Digestive Diseases · doi:10.1159/000512744 · Cited by 3
Jeong, H., Hong, Y. S., Kim, J. E., Lim, H.-S., Ahn, J. B., Shin, S. J., Park, Y. S., Kim, S. T., Han, S., Kim, T., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01110-9 · Cited by 2
Court, O. R., & Shemilt, K. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211017973 · Cited by 3
Mori, Y., Kikuchi, O., Horimatsu, T., Hara, H., Hironaka, S., Kojima, T., Kato, K., Tsushima, T., Ishihara, R., Mukai, K., et al. (2022) · Esophagus · doi:10.1007/s10388-021-00905-2 · Cited by 3
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases
Samoon, Z., Naher, S., Sjoquist, K. M., & Zalcberg, J. R. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2043276 · Cited by 3
New drug: Trifluridine/tipiracil for colorectal cancer
(2018) · Australian Prescriber · doi:10.18773/austprescr.2018.053 · Cited by 3
Randrian, V., Pernot, S., Sionneau, B., Smith, D. M., Lim, A., Touchefeu, Y., Gallois, C., Turpin, A., Javed, S., Guimbaud, R., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.830595 · Cited by 4
Bruckner, H. W., Bassali, F., Dusowitz, E., Gurell, D., Book, A., & Jager, R. D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276492 · Cited by 3
Regorafenib and trifluridine/tipiracil in real clinical practice
García‐Beloso, N., Romero‐Ventosa, E. Y., Gayoso-Rey, M., López‐López, A., Robles‐Torres, D., de Castro, N. M., & Piñeiro‐Corrales, G. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1316_20 · Cited by 3
Top Peritoneal Surface Malignancy Articles from 2022 to Inform your Cancer Practice
Mogal, H., & Shen, P. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15304-x · Cited by 3
Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer
Petrelli, F., Ghidini, A., Inno, A., & Barni, S. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000363 · Cited by 3
Kotaka, M., Ikeda, H., Tsujie, M., Yoshioka, S., Nakamoto, Y., Ishii, T., Kyogoku, T., Kato, T., Tsuji, A., & Kobayashi, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s104140 · Cited by 3
Becerra, C. R., Yoshida, K., Mizuguchi, H., Patel, M. R., & Hoff, D. D. V. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.856 · Cited by 3
Self-citationDual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer
Larsen, F. O., Markussen, A., Nielsen, D. L., Colville‐Ebeling, B., Riis, L. B., & Jensen, B. V. (2017) · Oncology · doi:10.1159/000475818 · Cited by 3
Prescriber adherence to antiemetic guidelines with the new agent trifluridine-tipiracil
Childs, D. S., Jacobson, A., Mitchell, J. L., Hubbard, J. M., Yoon, H. H., Finnes, H. D., Grothey, A., & Jatoi, A. (2017) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0314 · Cited by 3
Borelli, B., Zucchelli, G., Rossini, D., Cremolini, C., Antoniotti, C., Moretto, R., Marmorino, F., Colombo, C., Vannini, F., Delliponti, L., et al. (2018) · Colorectal Cancer · doi:10.2217/crc-2017-0023 · Cited by 4
Self-citationUnseld, M., Mader, R. M., Baumann, L., Veraar, C., Wrba, F., Waneck, F., Kieler, M., Bianconi, D., Berger, W., Sibilia, M. C., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.05.04 · Cited by 4
The clinical conundrum of managing 5‐fluorouracil–induced vasospasm in colorectal carcinoma
Nohria, A. (2019) · Cancer · doi:10.1002/cncr.32486 · Cited by 3
Potemski, P., Bujko, K., Rutkowski, A., & Krzakowski, M. J. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0030 · Cited by 6
on behalf of Oncology Network ASL1 Abruzzo, Bruera, G., Pepe, F., Malapelle, U., Staso, M. D., Mas, A. D., Giacomo, D. D., Scerbo, G., Santilli, M., Ciacco, E., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6636 · Cited by 3
Pan, W., Zhao, J., Zhang, S., Chen, X., Liang, W., & Li, Q. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108337 · Cited by 3
Shibutani, M., Wang, E., Okazaki, Y., Kashiwagi, S., Fukuoka, T., Iseki, Y., Hirakawa, K., & Ohira, M. (2021) · Anticancer Research · doi:10.21873/anticanres.15440 · Cited by 3
Ludwig, W.-D., & Schwabe, U. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_34 · Cited by 3
Redefining Later-Line Therapy in Metastatic Colorectal Cancer
Yee, K. (2017) · European Medical Journal · doi:10.33590/emj/10311880 · Cited by 3
Recommendations on intervention for hepatobiliary oncological surgery during the COVID-19 pandemic
Botella, A. G., Gómez‐Bravo, M. Á., Martino, M. D., Gastaca, M., Martín‐Pérez, E., Sánchez-Cabús, S., Pérez, B. S., López‐Ben, S., Sanjuán, J. C. R., López‐Andújar, R., et al. (2021) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2020.10.017 · Cited by 3
Giuliani, J., & Bonetti, A. V. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.009 · Cited by 3
Liver segment 2+3 living donation in liver transplantation for colorectal liver metastases
Dueland, S., & Line, P. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.11.15 · Cited by 3
Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer
Roda, D., Roselló, S., Huerta, M., & Cervantes, A. M. R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.030 · Cited by 3
Giuliani, J., Fiorica, F., Ponturo, G., Azzurro, M., Ruzzenente, A., & Bonetti, A. V. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221992546 · Cited by 3
Sotorasib in KRAS -Mutated Colorectal Cancer
Fakih, M. G., & Chao, J. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2406109 · Cited by 4
Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings
Nishizaki, D., & Eskander, R. N. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.017 · Cited by 2
Obeng‐Kusi, M., Martin, J. R., Roe, D. J., Erstad, B. L., & Abraham, I. L. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2365993 · Cited by 2
Zhang, J., Zhou, L., Zhao, S., & El‐Deiry, W. S. (2024) · Oncotarget · doi:10.18632/oncotarget.28602 · Cited by 3
Chang, Y.-W., Kuo, C.-N., Chang, C.-L., Hsu, J. C., & Ko, Y. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.376 · Cited by 2
Ros, J., Ucha, J. M., García‐Galea, E., Gomez, P., Martini, G., Balconi, F., Comas, R., Alonso, V., Rodríguez-Castells, M., Baraibar, I., et al. (2024) · Cancers · doi:10.3390/cancers16244140 · Cited by 2
Self-citationHe, C., Chi, J., Du, Z., Zhuang, Z., & Li, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1468532 · Cited by 2
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS
Massaro, G., Venturini, J., Rossini, D., Vannini, A., Brugia, M., Lavacchi, D., Conticello, C., Valle, I., Ravizza, D., Pillozzi, S., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104746 · Cited by 2
RET-fusion metastatic colon cancer responding to selpercatinib—a case report
Mullally, W. J., Huo, M., & O'Byrne, K. J. (2025) · Oxford Medical Case Reports · doi:10.1093/omcr/omaf120 · Cited by 2
Okechukwu, C. C., Ma, X., Li, W., D’Agostino, R., Rees, M. G., Ronan, M. M., Roth, J. A., & Gmeiner, W. H. (2025) · Cancers · doi:10.3390/cancers17172739 · Cited by 2
Koopman, M., García‐Carbonero, R., Pinto, C. M. D. S., Mitroshkin, A., Bodoky, G., Mineur, L., Bourgeois, V., Mare, M., Ruiz‐Casado, A., Montés, A. F., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100214 · Cited by 3
Bengala, E., Santini, D., & Picone, V. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101558 · Cited by 3
Maddalena, G., van der Pol, Y., Villarreal, O. E., Coker, O., Lee, H. M., Rivers, Z. T., Covert, W., Diao, S., Lonardi, S., Rogers, J. E., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf385 · Cited by 2
Victoria, I., Uboha, N. V., Jamal, R., Mejía, F. C., Ahumada, M., Im, S., Gomez‐Roca, C., Shapira‐Frommer, R., Perets, R., Yáñez, E., et al. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.01.003 · Cited by 2
Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
Zygulska, A. L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85027 · Cited by 2
Kim, S. T., Hong, J. Y., Lee, J., Park, J. O., Lim, H. Y., Kang, W. K., & Park, Y. S. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00691-z · Cited by 2
Bellio, H., Bertaut, A., Hervieu, A., Zanetta, S., Hennequin, A., Vincent, J., Palmier, R., Bengrine-Lefèvre, L., Ghiringhelli, F., & Fumet, J.-D. (2021) · Cancers · doi:10.3390/cancers13215472 · Cited by 2
Hamed, R., Marks, S., McElligott, H., Kalachand, R. D., Ibrahim, H., Atyani, S., Korpanty, G., & Osman, N. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2472 · Cited by 2
(2016) · Annals of Oncology · doi:10.1093/annonc/mdw358 · Cited by 2
Jamialahmadi, O., Salehabadi, E., Hashemi‐Najafabadi, S., Motamedian, E., Bagheri, F., Mancina, R. M., & Romeo, S. (2022) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2022.0122 · Cited by 4
Su, H., Min, J., Song, Y., Liu, L., Liu, L.-N., & Zhang, H. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04501-8 · Cited by 2
Lim, J. S. J., Ow, S. G. W., Wong, A. L. A., Lee, M. X. W., Chan, G. H. J., Low, J. L., Sundar, R., Choo, J. R. E., Chong, W. Q., Ang, Y. L. E., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113311 · Cited by 2
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_5 · Cited by 3
HARA, S., Sakai, D., Ikemura, K., Shintani, T., Yamamoto, T., Satoh, T., & Okuda, M. (2024) · Anticancer Research · doi:10.21873/anticanres.16917 · Cited by 2
Marschner, N. W., Seufferlein, T., Potthoff, K., Zahn, M., Uhlig, J., Dörfel, S., Karcher, A., Sauer, A., Maintz, C., Fruehauf, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100040 · Cited by 5
Kao, Y.-C. (2024) · American Journal of Cancer Research · doi:10.62347/ykzb8359 · Cited by 3
Guchelaar, N. A. D., Buck, S. A. J., van Doorn, L., Hussaarts, K. G. A. M., Sandberg, Y., van der Padt‐Pruijsten, A., Alphen, R. J. V., Poppe-Manenschijn, L., Vleut, I., de Bruijn, P., et al. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01390-3 · Cited by 2
Zhang, J., Yang, W., Liu, J., Wang, N., Ren, Z., Yang, T., Xie, G., Wu, G., & Sun, Y. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01443-1 · Cited by 2
Zhou, Y., Xu, Q., Wang, J., Leng, W., Cao, P., Chen, Y., Luo, D., Qiu, M., & Liu, J. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12652 · Cited by 2
Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer
Gou, M., Qian, N., Zhang, Y., Wang, Z., & Dai, G. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01120-9 · Cited by 2
Jacome, A. A. D. A., Mathias-Machado, M. C., Gil, M., Passarini, T. D. M., Cristofaro, S., de Moraes, E. D., Freitas, L., Prolla, G., Amorim, L. C., Paes, R. D., et al. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-524 · Cited by 3
Taïeb, J., Fakih, M., Liposits, G. I., Prager, G. W., Cutsem, E. V., Ciardiello, F., Amellal, N., Calleja, E. M., Liu, M., Roby, L., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1506075 · Cited by 2
Self-citationBekaii‐Saab, T., Sruti, I., Shi, J., Dai, W., Patton, G., Appukkuttan, S., Hocum, B. T., Katta, A., Babajanyan, S., & Cosgrove, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1591245 · Cited by 2
Hernando‐Calvo, A., Kurzrock, R., Gonzalez, N. S., Magidi, S., Bresson, C., Wunder, F., Pretelli, G., Casado, A. M., & El‐Deiry, W. S. (2025) · Oncotarget · doi:10.18632/oncotarget.28744 · Cited by 5
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.